NZ604089A - Multivalent glycopeptide constructs and uses thereof - Google Patents

Multivalent glycopeptide constructs and uses thereof

Info

Publication number
NZ604089A
NZ604089A NZ604089A NZ60408911A NZ604089A NZ 604089 A NZ604089 A NZ 604089A NZ 604089 A NZ604089 A NZ 604089A NZ 60408911 A NZ60408911 A NZ 60408911A NZ 604089 A NZ604089 A NZ 604089A
Authority
NZ
New Zealand
Prior art keywords
multivalent
glycopeptide
constructs
glycopeptide constructs
immunogenic glycoconjugate
Prior art date
Application number
NZ604089A
Other languages
English (en)
Inventor
Samuel J Danishefsky
Guangbin Yang
Karthik Iyer
Govind Ragupathi
Philip O Livingston
Jianglong Zhu
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of NZ604089A publication Critical patent/NZ604089A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NZ604089A 2010-06-11 2011-06-10 Multivalent glycopeptide constructs and uses thereof NZ604089A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35372210P 2010-06-11 2010-06-11
PCT/US2011/040074 WO2011156774A2 (en) 2010-06-11 2011-06-10 Multivalent glycopeptide constructs and uses thereof

Publications (1)

Publication Number Publication Date
NZ604089A true NZ604089A (en) 2015-03-27

Family

ID=45098716

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ604089A NZ604089A (en) 2010-06-11 2011-06-10 Multivalent glycopeptide constructs and uses thereof

Country Status (8)

Country Link
US (1) US9493580B2 (enExample)
EP (1) EP2579893A4 (enExample)
JP (1) JP6050227B2 (enExample)
CN (1) CN103108654A (enExample)
AU (1) AU2011265184B2 (enExample)
CA (1) CA2801922A1 (enExample)
NZ (1) NZ604089A (enExample)
WO (1) WO2011156774A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1048819B (en) 1999-08-20 2006-11-10 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
AU2009268349C1 (en) 2008-07-11 2015-01-22 Sloan-Kettering Institute For Cancer Research Glycopeptide constructs and uses thereof
US8900635B2 (en) 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
KR20150060986A (ko) * 2012-10-02 2015-06-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 비선형 사카라이드 컨주게이트
CN111499679B (zh) * 2013-01-04 2021-07-06 台湾浩鼎生技股份有限公司 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂
HK1222569A1 (zh) * 2013-09-17 2017-07-07 Obi Pharma, Inc. 用於诱导免疫反应的糖疫苗组合物及其治疗癌症的用途
WO2015048408A1 (en) * 2013-09-27 2015-04-02 Virginia Tech Intellectual Properties, Inc. Cross-metathesized polysaccharide derivatives and processes for preparing them
US9084726B2 (en) 2013-11-26 2015-07-21 Humanetics Corporation Suspension compositions of physiologically active phenolic compounds and methods of making and using the same
ES2865148T3 (es) 2014-03-13 2021-10-15 Univ Basel Ligandos de carbohidratos que se unen a los anticuerpos IgM contra la glucoproteína asociada a mielina
US10851179B2 (en) 2014-03-14 2020-12-01 Virginia Tech Intellectual Properties, Inc. Polysaccharide derivatives and cross-metathesis processes for preparing them
US20170143810A1 (en) 2014-03-19 2017-05-25 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
JP6590474B2 (ja) * 2014-09-25 2019-10-16 国立大学法人埼玉大学 化学架橋ペプチドの作製方法、その方法を用いて作製した化学架橋ペプチド及びそのペプチドを用いて構築したｃＤＮＡディスプレイ法によるペプチドライブラリ
AR105910A1 (es) * 2015-09-04 2017-11-22 Obi Pharma Inc Matrices de glicano y método de uso
HK1252262A1 (zh) 2015-09-16 2019-05-24 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
TWI697333B (zh) 2016-04-22 2020-07-01 台灣浩鼎生技股份有限公司 經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法
JP2019527690A (ja) * 2016-07-27 2019-10-03 オービーアイ ファーマ，インコーポレイテッド 免疫原性／治療用グリカン組成物およびその使用
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ，インコーポレイテッド ヒト抗体、医薬組成物及び方法
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5576894A (en) 1978-12-05 1980-06-10 Towa Kasei Kogyo Kk Epimerization of aldose
ZA888209B (en) 1987-11-03 1990-07-25 Syntex Inc Vaccine adjuvant
US5708163A (en) 1994-03-15 1998-01-13 Sloan-Kettering Institute Of Cancer Research Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
US6303120B1 (en) 1994-03-15 2001-10-16 Memorial Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the lewis y epitope and uses thereof
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
CA2277867A1 (en) 1997-01-13 1998-07-16 Sloan-Kettering Institute For Cancer Research Colon cancer kh-1 and n3 antigens
US7550146B2 (en) 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
WO1998046246A1 (en) 1997-04-16 1998-10-22 Sloan-Kettering Institute For Cancer Research α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
EP0996451B1 (en) 1997-05-20 2005-01-05 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
JPH1135594A (ja) 1997-07-24 1999-02-09 Meiji Milk Prod Co Ltd ムチン型糖鎖合成中間体
CA2304599A1 (en) 1997-09-25 1999-04-01 Sloan-Kettering Institute For Cancer Research Fucosyl gm1-klh conjugate vaccine against small cell lung cancer
DE19802748A1 (de) 1998-01-26 1999-07-29 Chemtec Leuna Ges Fuer Chemie Verfahren zur enzymatischen Synthese von Glycoaminosäurederivaten
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
EP1091751A4 (en) 1998-03-25 2005-01-19 Sloan Kettering Institutefor C TRIMERIC OXYGENIC BINDING GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USE THEREOF
CA2332786A1 (en) 1998-05-29 1999-12-02 Epimmune Inc. Identification of broadly reactive dr restricted epitopes
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
HK1048819B (en) 1999-08-20 2006-11-10 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EP2263465A1 (en) 2001-07-06 2010-12-22 Sloan-Kettering Institute for Cancer Research Polyvalent conjugate vaccine for cancer
AU2003302235A1 (en) 2002-12-03 2004-06-23 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
WO2004060915A2 (en) 2002-12-03 2004-07-22 Sloan-Kettering Institute For Cancer Research Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
AU2004286919A1 (en) 2003-09-05 2005-05-19 Sloan-Kettering Institute For Cancer Research Method for preparing polyfunctionalized peptides and/or proteins via native chemical ligation
CA2674269C (en) 2006-01-03 2018-06-12 University Of Georgia Research Foundation, Inc. Three component glycolipopeptides
CA2654073A1 (en) 2006-06-08 2007-12-21 University Of Georgia Research Foundation, Inc. Liposome-mediated native chemical ligation
AU2009268937A1 (en) 2008-06-16 2010-01-14 Aj Park Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment
AU2009268349C1 (en) * 2008-07-11 2015-01-22 Sloan-Kettering Institute For Cancer Research Glycopeptide constructs and uses thereof

Also Published As

Publication number Publication date
CN103108654A (zh) 2013-05-15
JP2013528229A (ja) 2013-07-08
CA2801922A1 (en) 2011-12-15
AU2011265184B2 (en) 2016-08-04
EP2579893A2 (en) 2013-04-17
US9493580B2 (en) 2016-11-15
EP2579893A4 (en) 2014-01-01
WO2011156774A3 (en) 2012-04-19
JP6050227B2 (ja) 2016-12-21
WO2011156774A2 (en) 2011-12-15
AU2011265184A1 (en) 2013-01-10
US20130095173A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
NZ628449A (en) Neisseria meningitidis compositions and methods thereof
NZ622048A (en) Hybrid polypeptides including meningococcal fhbp sequences
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
MX2012001194A (es) Peptidos tau antigenicos y usos de los mismos.
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CA2830786C (en) Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
WO2010096418A3 (en) Antibody molecules having specificity for human ox40
EP2562183A8 (en) Novel immunogenic epitopes for immunotherapy
MX363307B (es) Plataformas para suministro de antigenos.
WO2009104074A3 (en) Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
MX2011010955A (es) Terapia complementaria contra el cancer.
WO2011113819A3 (en) Diagnosis and treatment of cancer based on avl9
PH12012501898A1 (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
NZ597858A (en) Vaccines and compositions against streptococcus pneumoniae
WO2011156751A3 (en) Immunogenic vaccine
WO2007118660A3 (en) Her-2/neu multi-peptide vaccine
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов

Legal Events

Date Code Title Description
S23 Proceedings under section 23: mention of inventor as such in patent

Free format text: INVENTOR SABBATINI, PAUL REMOVED

Effective date: 20130117

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20150731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUN 2019 BY CPA GLOBAL

Effective date: 20180426

LAPS Patent lapsed